These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31504327)

  • 1. Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus.
    Saeed S; Strumpf E; Moodie EEM; Wong L; Cox J; Walmsley S; Tyndall M; Cooper C; Conway B; Hull M; Martel-Laferriere V; Gill J; Wong A; Vachon ML; Klein MB;
    Clin Infect Dis; 2020 Jul; 71(2):363-371. PubMed ID: 31504327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
    Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
    J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
    Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
    Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.
    Taylor LE; Swan T; Matthews GV
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S118-24. PubMed ID: 23884059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?
    Panagiotoglou D; Krebs E; Min JE; Olding M; Ahamad K; Ti L; Montaner JSG; Nosyk B
    Int J Drug Policy; 2017 Sep; 47():169-176. PubMed ID: 28578865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals.
    Coyle CR; Gicquelais RE; Genberg BL; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH
    Drug Alcohol Depend; 2023 Dec; 253():. PubMed ID: 38456165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
    Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
    Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals.
    Nitulescu R; Young J; Saeed S; Cooper C; Cox J; Martel-Laferriere V; Hull M; Walmsley S; Tyndall M; Wong A; Klein MB;
    Int J Drug Policy; 2019 Mar; 65():41-49. PubMed ID: 30594080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
    Martin NK; Boerekamps A; Hill AM; Rijnders BJA
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25062. PubMed ID: 29633560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
    Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
    Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
    Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
    Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
    Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
    J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
    AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era.
    Falade-Nwulia O; Gicquelais RE; Astemborski J; McCormick SD; Kirk G; Sulkowski M; Thomas DL; Mehta SH
    Liver Int; 2020 Oct; 40(10):2407-2416. PubMed ID: 32770638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
    Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
    Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
    Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
    J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.